Status:
RECRUITING
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Lead Sponsor:
Riccardo Guglielmo
Conditions:
Depression and Quality of Life
Treatment Resistant Depression (TRD)
Eligibility:
All Genders
18-74 years
Brief Summary
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, i...
Eligibility Criteria
Inclusion
- Inclusion criteria were: (a) age 18-74, (b) DSM-5 diagnosis of a major depressive episode (MDE), (c) failure to respond to at least 2 prior antidepressant treatments (ADTs), and (d) current treatment with an SSRI or SNRI for which esketamine nasal spray was deemed appropriate.
Exclusion
Key Trial Info
Start Date :
November 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07146503
Start Date
November 1 2022
End Date
August 1 2030
Last Update
September 24 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Policlinico San Martino
Genova, Ge, Italy, 16132
2
Csm Dds 8
Genova, Ge, Italy, 16158
3
Università di Chieti
Chieti, Italy, 66100
4
ASST Fatebenefratelli Sacco
Milan, Italy, 20157